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PCongenital Heart Disease
Impaired Apoptosis of Pulmonary Endothelial Cells Is
Associated With Intimal Proliferation and Irreversibility
of Pulmonary Hypertension in Congenital Heart Disease
Marilyne Lévy, MD, PHD,*† Christelle Maurey, DVM,* David S. Celermajer, MBBS, DSC, FRACP,‡
Pascal R. Vouhé, MD,† Claire Danel, MD,* Damien Bonnet, MD, PHD,§
Dominique Israël-Biet, MD*
Paris, France; and Sydney, Australia
Objectives This study sought to assess the cellular and histologic basis of irreversible pulmonary hypertension (PHT) in the
clinical setting of congenital heart disease (CHD).
Background Although many children with CHD develop pulmonary vascular disease, it is unclear why this complication is re-
versible after complete repair in some cases but irreversible in others. Because failure of endothelial cell apopto-
sis might lead to intimal proliferation and lack of reversibility of PHT, we investigated this and other key markers
of vasoactivity and angiogenesis in subjects with PHT and CHD.
Methods We assessed antiapoptotic and proapoptotic markers in vascular and perivascular cells in lung biopsy samples
from 18 patients with CHD, 7 with reversible and 11 with irreversible PHT, and 6 control patients. Immunostain-
ing for endothelial nitric oxide synthase, vascular endothelial growth factor, and CD34 (markers of vasoactivity
and neoangiogenesis) was also performed.
Results The antiapoptotic protein Bcl-2 was highly expressed by pulmonary endothelial cells in all cases of irreversible
PHT but in no cases of reversible PHT, nor in control patients (p  0.001). Intimal proliferation was present in
10 of 11 irreversible PHT cases, but never observed in reversible PHT (p  0.001). Similarly, perivascular inflam-
matory T-cells expressed more antiapoptotic proteins in irreversible PHT (p  0.01). Irreversible PHT cases were
also more likely to show compensatory upregulation of vascular endothelial growth factor and new small vessel
formation at the sites of native vessel stenosis or occlusion (p  0.001).
Conclusions Irreversible PHT is strongly associated with impaired endothelial cell apoptosis and antiapoptotic signaling from
perivascular inflammatory cells. These changes are associated with intimal proliferation and vessel narrowing,
and thereby may contribute to clinical outcomes associated with pulmonary hypertension. (J Am Coll Cardiol
2007;49:803–10) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.049d
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mlthough particular congenital heart diseases (CHD) are
ell recognized to lead to early and important pulmonary
ascular disease (PVD), there is a wide range of pulmonary
ascular responses for any given underlying lesion (1,2). For
xample, truncus arteriosus or atrioventricular septal defect
re often but not always associated with PVD in infancy (3).
urthermore, the important clinical parameter of reversibil-
ty of PVD is often difficult to predict in patients, even with
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ôpital Européen Georges Pompidou, Paris, France. This study was supported by
eg Poix, Paris, France.i
Manuscript received June 16, 2006; revised manuscript received September 12,
006, accepted September 19, 2006.etailed knowledge of their abnormal intracardiac anatomy
nd physiology. The pathogenic mechanisms that lead to
irreversible” PVD and thus pulmonary hypertension
PHT) (that which fails to reverse after correction of the
nderlying anatomical defect) are therefore poorly under-
tood in subjects with CHD.
Apoptosis is the process of normal programmed cell
eath that allows normal cell turnover and remodeling in
he vasculature (4), and recent data have implicated a
esistance to apoptosis in the pathogenesis of vascular
roliferation in experimental and cell culture studies (5,6).
ndothelial dysfunction is also known to complicate PHT
n the setting of CHD in vivo in humans (7,8).
We therefore hypothesized that resistance to apoptosis
ight characterize the pulmonary vessels of subjects withrreversible PHT, with consequent unregulated intimal
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Apoptotic Markers in Congenital Heart Disease February 20, 2007:803–10proliferation, vessel stenosis,
and/or occlusion and compensa-
tory neoangiogenesis with local
up-regulation of vascular endo-
thelial growth factor (VEGF).
To explore these possibilities, we
undertook detailed histology and
cellular immunohistochemistry
studies of the lungs of subjects
with CHD and either irreversible
or reversible PHT.
Methods
Study population. Eighteen
consecutive patients with CHD
and PHT, excluding all patients
with trisomy 21, who underwent
cardiac surgery at Necker-Enfants
alades Hospital and in whom a lung biopsy specimen was
btained, were enrolled in the study. Table 1 shows their
linical and hemodynamic characteristics and postoperative
utcomes. Preoperative hemodynamic evaluation was per-
ormed in all patients, including measurements of pulmo-
ary pressure and determination of shunt by oximetry before
nd after inhaled nitric oxide (NO). In all these patients,
reoperative hemodynamic data did not clearly establish
hether or not the PHT would be reversible after pulmo-
ary artery banding or lesion repair. Therefore, all of these
atients underwent either complete repair or palliative
urgery, and lung biopsy was performed for histomorpho-
Abbreviations
and Acronyms
CHD  congenital heart
disease
eNOS  endothelial nitric
oxide synthase
iNOS  inductible nitric
oxide synthase
NO  nitric oxide
PHT  pulmonary
hypertension
PVD  pulmonary vascular
disease
PVR  pulmonary vascular
resistance
VEGF  vascular
endothelial growth factor
atient Characteristics and Postoperative Outcome
Table 1 Patient Characteristics and Postoperative Outcome
Patient # Gender
Age*
(yrs) Diagnosis
PAP
(S/D) Q
Reversible PHT
1 M 3 SV 60/25
2 F 4 SV 59/26
3 F 5 SV 75/35
4 M 6 VSD 55/30
5 M 3 SV 68/28
6 F 32 ASD 65/35
7 F 42 ASD 70/33
Irreversible PHT
8 M 5 TGA/VSD 65/30
9 F 2 SV 75/36
10 F 24 SV 67/26
11 M 2 VSD 86/36
12 M 15 VSD 75/35
13 F 13 SV 62/26
14 M 7 VSD 59/25
15 F 33 ASD 60/25
16 M 3 SV 58/30
17 F 3 VSD 55/30
18 F 1 VSD 70/20
Age at lung biopsy.
ASD  atrial septal defect; iNO  inhaled nitric oxide; NA  not available; PAP (S/D)  pulmonary arte
ow; QS  systemic blood flow; SV  single ventricle; TCPC  total cavopulmonary connection; TGA  tetric analysis of pulmonary arteries. Patients were sepa-
ated into 2 groups on an a posteriori evaluation of pulmo-
ary pressure after 1 year. Seven had normal pulmonary
rterial pressure (reversible PHT) and 11 still had elevated
ulmonary vascular resistance (PVR) and pulmonary arterial
ressure (irreversible PHT). These 2 groups were similar in
erms of age and preoperative level of PHT. Longer-term
ostoperative follow-up (median 2 years, range 1 to 10 years)
onfirmed that pulmonary pressure remained normal in all
atients with “reversible” PHT. One of these patients (Patient
1) died with sepsis in the postoperative course of a subsequent
peration (total cavopulmonary connection). There were 2
arly and 2 late deaths related to PHT in the irreversible PHT
roup. One patient (Patient #15) who had suprasystemic PHT
n the postoperative course is still alive after 10 years, and the
ulmonary systolic pressure was estimated as two-thirds of the
ystemic pressure. Six patients with normal lung histology who
ied of extracardiac and extrapulmonary causes were studied as
ontrol patients.
issue specimens. Lung tissue, obtained during cardiac
urgery, was formalin-fixed and paraffin-embedded. Serial
-m-thick sections were stained with hematoxylin and
osin and modified orcein for elastic fibers to allow identi-
cation of morphologic structures and precise correlation
ith patterns of immunoreactivity. Pulmonary vascular
tructures were analyzed using quantitative morphometric
echniques as previously described (9). Intimal thickening,
educed arterial concentration, occlusive fibrosis, plexiform
esions, and dilatation of distal arteries were looked for and
onsidered as irreversible vascular lesions.
QP/QS
After iNO
Surgical
Procedure
Postoperative PAP
(S/D)
Follow-Up
(yrs)
NA Banding 25/12 TCPC (1), dead
3 Banding 25/10 TCPC (2)
2 Banding 20/10 TCPC (1)
3 Closure 30/15 20/10 (7)
2.8 Banding 35/12 20/10 (1)
2.7 Closure 35/15 30/15 (10)
2.5 Closure 35/20 22/10 (5)
NA Senning 80/40 Alive (2)
2 Banding 90/38 Alive (1)
2 Banding 100/60 Dead
NA Closure 95/50 Alive (1)
2 Closure 90/40 Alive (1)
NA Banding 110/55 Dead
2.5 Closure 85/40 Alive (2)
2 Closure 110/50 70/40 (10)
2 Banding 85/40 Dead (2)
2 Closure 90/40 Alive (1)
2.3 Closure 60/30 Dead (0.5)P/QS
2
2.1
1.6
2
1.7
1.8
2.7
1.3
1.7
1.6
1.9
1.5
2
2.5
1.5
1.5
1.8
1.2rial pressure (systolic/diastolic) (mm Hg); PHT  pulmonary hypertension; QP  pulmonary blood
ransposition of great arteries; VSD  ventricular septal defect.
I
w
i
t
C
D
i
C
f
n
w
(
a
n
r
C
C
t
c
B
d
p
h
w
t
n
a
v
e
t
e
g
m
t
t
i
i
S
b
e
s
s
s
p
s
g
W
f
t
R
H
t
i
I
o
a
O
i
i
e
T
t
m
(
a
805JACC Vol. 49, No. 7, 2007 Lévy et al.
February 20, 2007:803–10 Apoptotic Markers in Congenital Heart Diseasemmunohistochemical analysis. Markers of apoptosis
ere assessed in vascular cells and inflammatory cells using
mmunohistochemistry with the corresponding primary an-
ibodies, anti–caspase-3 (BD Pharmingen, Le Pont de
laix, France), -p53 (monoclonal anti-human p53 protein,
ako Corp., Carpenteria, California), and -Bcl-2 antibod-
es (monoclonal anti-human BCL2 oncoprotein, Dako
orp.) (10).
The vascular expression of vasoactive and angiogenic
actors, endothelial nitric oxide synthase (eNOS), inductible
itric oxide synthase (iNOS), and VEGF was also assessed
ith the corresponding primary antibodies anti-eNOS
Transduction Laboratory, Lexington, United Kingdom),
nti-iNOS, and anti-VEGF (A-20, Santa Cruz Biotech-
ology, Santa Cruz, California). In addition, antibodies
ecognizing endothelial polyclonal anti-CD34 (Dako
orp.) or inflammatory cells (anti-CD3, anti-CD68, anti-
D79, anti-tryptase, and anti-elastase [Dako Corp.]) iden-
ifying T lymphocytes, macrophages, B lymphocytes, mast
ells, and polymorphonuclear cells, respectively, were used.
riefly, tissue sections were deparaffinized in toluene, rehy-
rated, and heated for 40 min in buffered citrate at pH 6, or
H 9 for the anti–caspase-3. Slides were incubated in
ydrogen peroxide to block endogenous peroxidase activity,
ashed in tris-buffered saline, and incubated for 1 h with
he primary antibodies or with normal serum used as a
egative control. Slides were then incubated for 15 min with
biotinylated secondary antibody and stained with strepta-
idin labeled with peroxidase, according to the manufactur-
r’s instructions (Dako Corp.). The slides were then coun-
erstained using Harris hematoxylin.
The intensity of the immunostaining in the arteries of
xternal diameter 100 to 200 m or 50 to 100 m was
raded semi-quantitatively from 0  no staining to 3 
aximal staining. Inflammatory infiltrates were analyzed in
Figure 1 Lung Biopsy Sections Showing Histological Changes i
Intra-Acinar Pulmonary Arteries in Reversible PHT and
(A) Increased wall thickness (arrow) and thin and regular intimal layer (arrowhead
thickness (arrow) associated with intimal thickening (arrowhead) in irreversible puerms of cell type and density, scored as 0 no labeled cells,
o 3  maximal density. The grading was performed by 2
ndependent investigators who were blinded to all clinical
nformation.
tatistical analysis. No significant differences were noted
etween observers, and we have previously documented
xcellent interobserver correlations for the parameters mea-
ured in this study (11). For each marker, because the
taining score intensities were similar in arteries of different
izes, we pooled the corresponding results. Data are ex-
ressed as a score of immunodetection (mean  SD of the
cores obtained by each investigator). Comparisons between
roups were assessed using the nonparametric Mann-
hitney U test analysis. Correlation between vasoactive
actor scores was analyzed using the Spearman test correla-
ion. A value of p  0.05 was considered significant.
esults
istomorphometric data. Lung tissue specimens showed
he presence of intimal proliferation lesions in 10 of 11 cases of
rreversible PHT and in no cases of reversible PHT (Fig. 1).
ntimal proliferation appeared as more advanced lesions in 8
f these patients, whereas concentric laminar intimal fibrosis
nd plexiform lesions were observed in the remaining 2.
nly 1 patient of this group (Patient #17) did not show
ntimal proliferation.
Both groups of PHT patients showed a comparably
ncreased mean percentage wall thickness and abnormal
xtension of muscle into distal pulmonary arteries (Table 2).
hese values were markedly increased compared with con-
rol patients (p  0.0001). Patients’ values were also
arkedly increased compared with normal values for age
p  0.001) (9). Lung biopsies showed normal pulmonary
rteries in all subjects in the control group.
ersible PHT
Increased wall
ry hypertension (PHT).n
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Apoptotic Markers in Congenital Heart Disease February 20, 2007:803–10arkers of apoptosis. The antiapoptotic marker Bcl-2 was
xclusively expressed in irreversible PHT by endothelial
ells from arteries with severe intimal fibrosis and never
xpressed in reversible PHT (Fig. 2A). Very few smooth
uscle cells expressed Bcl-2 in irreversible PHT. Markers
f apoptosis caspase-3 and p53 were expressed by the
ndothelial layer in both groups of patients (Figs. 2B and
C). Immunostaining for caspase-3 and p53 was not ob-
erved in smooth muscle cells. Very few cells expressed
aspase-3 or p53 in the control group (p  0.001 compared
ith CHD-PHT).
nflammatory infiltrates. In addition to the aforemen-
ioned morphologic alterations, patients with PHT differed
rom control patients in that the majority showed a consis-
ent inflammatory infiltrate in the bronchovascular areas.
hese infiltrates were present in all patients with irreversible
HT (11 of 11 patients) and in 5 of 7 patients with
eversible PHT. Inflammatory cells mainly consisted of
D3 T lymphocytes (89  23%) with a few macrophages
7  2%) and a few polymorphonuclear cells (3  1%).
ast cells when present were not localized in either inflam-
atory infiltrate or in the pulmonary arteries. These infil-
rates were similar between the 2 PHT groups in terms of
ell density and cell type. We then assessed the apoptotic
roperties of inflammatory cells in the 2 groups. The
ntiapoptotic protein Bcl-2 was largely expressed in irre-
ersible PHT and poorly expressed in reversible PHT (Fig.
A). Conversely, the proapoptotic proteins caspase-3 and
53 were strongly expressed by inflammatory cells in revers-
ble PHT but not expressed in irreversible PHT (p 0.001)
Figs. 3B and 3C). Thus, in irreversible CHD-PHT,
nflammatory cells showed decreased proapoptotic activity
nd increased antiapoptotic marker expression, suggesting
hat the nature of the inflammatory process might play a
ole in the course of CHD-PHT.
Pulmonary vascular iNOS expression, involved in the
nflammatory processes, was similarly increased in the 2
HT groups compared with control patients (p  0.001).
arkers of compensatory neoangiogenesis. Endothelial
OS was detected exclusively in vascular endothelial cells of
ll size arteries. Its expression was higher in irreversible than
n reversible PHT patients and particularly intense in severe
ascular lesions (eNOS scores 2.4  0.4 and 1.2  0.5,
espectively; p  0.001) (Fig. 4A). In control patients,
ercentage WT of Intra-Acinar Pulmonaryrteries With ED From 50 to 200 m
Table 2 Percentage WT of Intra-Acinar PulmonaryArteries With ED From 50 to 200 m
WT (%) of Arteries With
ED  50–100 m
WT (%) of Arteries With
ED  100–200 m
Normal values 7.4 2.5 7.2 1.8
Control patients 7.6 3.2* 7.1 5.7*
Reversible PHT 37.3 5.1 42.7 8.8
Irreversible PHT 36.4 7.7 39.8 11.2
p  0.01 compared with both groups of patients.
ED  external diameter; PHT  pulmonary hypertension; WT  wall thickness.NOS expression was lower than in both PHT groups i0.65  0.2, p  0.05 vs. reversible PHT and p  0.001 vs.
rreversible PHT).
Vascular endothelial growth factor was immunolocalized
n vascular endothelial cells of all size arteries (Fig. 4B). Its
xpression was higher in irreversible than in reversible PHT
atients (2.9  0.5 and 0.5  0.1, respectively, p  0.001).
he VEGF expression was comparable in reversible PHT
nd control patients (0.6  0.1).
The eNOS expression correlated with VEGF expression
nly in irreversible PHT (r  0.96; p  0.001). This,
ogether with CD34 immunostaining in the vicinity of all
ccluded arteries, suggests neoangiogenesis in irreversible
HT (Fig. 4C).
iscussion
he pathophysiologic mechanisms that determine the re-
ersible or irreversible nature of PHT that commonly
omplicate certain congenital heart diseases remain unclear.
rreversible PHT is difficult to predict on the basis of
reoperative testing and has adverse long-term conse-
uences. In the present study, we document a highly
ignificant association between failure of endothelial cell
poptosis, intimal proliferation, and irreversible PHT in
hildren with high-risk CHD.
Previous studies in idiopathic PHT have recently impli-
ated a failure of vascular smooth muscle apoptosis in the
isease pathogenesis (12,13). However, data about endothe-
ial cell apoptosis and proliferation are scarce in idiopathic
HT (5,14) and absent for PHT complicating CHD. Other
ecent studies have suggested a role for periarterial inflam-
atory cell mediators in the pathogenesis of PHT (15,16).
For these reasons, we sought to determine whether
ltered endothelial cell and or periarterial inflammatory cell
henotype might account for the development of irrevers-
ble pulmonary vascular changes in CHD. To answer these
uestions, we analyzed pulmonary biopsies from patients
ndergoing cardiac surgery for CHD and elevated PVR to
nalyze vascular expression of apoptotic and angiogenic
arkers in reversible or irreversible PHT in the setting of
HD (as assessed by the gold standard test of presence or
bsence of residual PHT judged by hemodynamic status 1
ear after surgery).
We first confirmed that all PHT patients showed the
xpected histomorphologic vascular alterations in terms of
rterial wall thickness (1,2), but intimal damage was ob-
erved only in irreversible PHT. One patient of the irre-
ersible PHT group did not show any intimal lesion, in
eeping with the fact that a few patients can maintain high
ulmonary vascular resistances despite mild histologic vas-
ular changes (17). This underscores the fact that histomor-
hometric parameters are not always sufficient to predict the
utcome in PHT.
The role of proapoptotic and antiapoptotic proteins in
HT has been suggested, both as an initiating mechanism
n the pathogenesis of PHT and as a potential mechanism
f
(
b
I
p
g
i
a
m
f
c
c
a
s
e
f
o
t
s
807JACC Vol. 49, No. 7, 2007 Lévy et al.
February 20, 2007:803–10 Apoptotic Markers in Congenital Heart Diseaseor the proliferation of apoptosis-resistant vascular cells
5,18). In our study, markers of apoptosis markedly differed
etween subjects with reversible and irreversible PHT.
ndeed, although the proapoptotic markers caspase-3 and
53 were expressed in endothelial cells in patients of both
roups, the antiapoptotic protein Bcl-2 was expressed only
n the endothelial cells of severely damaged pulmonary
rteries of patients with irreversible PHT. The TdT-
ediated dUTP-biotin end labeling staining was not per-
ormed in these experiments because this stain is not
Figure 2 Vascular Immunostaining for Markers of Apoptosis in
The antiapoptotic protein Bcl-2 is not expressed in reversible pulmonary hypertens
ible PHT in all cases (A). Endothelial cells of both groups expressed markers of a
thelial layer.ompletely specific for apoptosis but also identifies necrotic eells (19), thus suggesting a superior specificity of caspase-3
nd p53 protein expression as proapoptotic markers.
This observation is consistent with a recent in vitro study
uggesting that pulmonary endothelial cell apoptosis is an
arly mechanism in the pathogenesis of idiopathic PHT
ollowed by proliferation of apoptotic-resistant cells (5).
In our series, although all PHT patients had proliferation
f smooth muscle cells with increased medial wall thickness,
he expression of the antiapoptotic protein Bcl-2 was low in
mooth muscle cells. Our data may suggest that the remod-
rsible PHT and Irreversible PHT
T), but by endothelial cells of severely damaged pulmonary arteries in irrevers-
is caspase-3 (B) and p53 (C). The arrow indicates immunostaining in the endo-Reve
ion (PH
poptosling process in the course of CHD-PHT preferentially
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Apoptotic Markers in Congenital Heart Disease February 20, 2007:803–10nvolves an acquired apoptosis-resistant phenotype in endo-
helial cells rather than a central role of apoptosis-resistant
mooth muscle cells as proposed for idiopathic PHT
12,13). Apoptosis-resistant endothelial cells are then more
ikely to produce intimal proliferation and occlusion of distal
ntrapulmonary arteries, and then likely to induce compen-
atory development of neovessels in the vicinity of severely
ltered native vessels. Consistent with this hypothesis, we
ound CD34 structures surrounding all occluded vessels.
oth VEGF and eNOS are involved in neoangiogenesis
20–23). Although eNOS expression was increased in all
atients compared with control patients, eNOS expression
as significantly higher in irreversible compared with re-
ersible PHT. Increased eNOS expression in advanced
ulmonary vascular lesions has already been described in the
Figure 3 Apoptotic Properties of Inflammatory Cells in the Bron
In irreversible pulmonary hypertension (PHT) the antiapoptotic protein Bcl-2 (A) is
for apoptotic markers is very low. The proapoptotic proteins caspase-3 (B) and p-5linical setting of Eisenmenger syndrome (irreversible tHT) (24,25), but no data are available on reversible PHT
n humans.
The current findings are consistent with experimental
tudies suggesting an adaptive compensatory response to
ncreased pulmonary blood flow and arterial pressure
26,27). In irreversible PHT, however, the overexpression of
NOS is associated with impaired NO-dependent pulmo-
ary vasodilation (7,8). This is perhaps consistent with
ysfunction of NO production in favor of superoxide, as
ocumented in advanced systemic arterial disease (28). We
lso found an overexpression of the angiogenic protein
EGF in association with irreversible PHT, similar to that
een previously in studies performed in Eisenmenger lesions
29,30). Also, VEGF has been implicated in endothelial cell
urvival by inducing upregulation of the antiapoptotic pro-
ascular Area in Reversible PHT or Irreversible PHT
ly expressed by inflammatory cells, whereas immunostaining
are strongly expressed by inflammatory cells in reversible PHT.chov
strong
3 (C)ein Bcl-2 (31). Therefore, VEGF could induce both
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February 20, 2007:803–10 Apoptotic Markers in Congenital Heart Diseaseurvival of proliferative endothelial cells and compensatory
ngiogenesis in irreversible PHT. It is of note that severely
ccluded vessels with strong eNOS and VEGF expression
ere all surrounded by important CD34 structures, sug-
esting a paracrine and autocrine effect on new small vessel
ormation. This compensatory up-regulation of VEGF in
esponse to occluded vessels has also been found in systemic
rteriopathy, such as diabetic retinopathy and age-related
acular degeneration (20,32).
Finally, 16 of 18 patients showed inflammatory infiltrates
n perivascular areas, mostly consisting of T cells. The
ontribution of the inflammatory process to the pathogen-
sis of idiopathic PHT recently has been suggested (15,16),
ut data on its role in CHD-PHT are scarce (33). Here we
Figure 4 Immunostaining for Markers of Angiogenesis in Patien
Reversible PHT and Irreversible PHT Compared With C
Endothelial immunostaining (arrows) for endothelial nitric oxide synthase (eNOS) (
PHT and weakly expressed in control patients. Immunostaining for vascular endoth
strongly expressed in endothelial cells in irreversible PHT. Strong endothelial CD34
severe intimal damage (C).ave shown the presence of important inflammatory infil- arates located in the bronchopulmonary spaces, but whether
hese infiltrates are of primary or secondary concern regard-
ng the pathogenesis of pulmonary vascular disease remains
nclear.
We now document an additional potential mechanism
or an interaction between inflammation and vascular
hanges associated with CHD: the increased expression of
ntiapoptotic and reduced expression of proapoptotic factors
y infiltrative leucocytes in irreversible PHT. This might
uggest that irreversible PHT is associated with an increased
apacity of the inflammatory infiltrate to contribute to
orsening vascular injury.
In this study, only cross-sectional cellular and histomor-
hometric data are available, although we had some clinical
ith
l Patients
ore pronounced in irreversible pulmonary hypertension (PHT) than in reversible
rowth factor (VEGF) (B) is weak in reversible PHT and control patients and
nostaining (arrows) shows neovessels surrounding pulmonary arteries withts W
ontro
A) is m
elial g
immund hemodynamic information. Thus associations can be
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Apoptotic Markers in Congenital Heart Disease February 20, 2007:803–10ade only between the parameters measured and reversible
r irreversible PHT, rather than any cause-and-effect rela-
ionship. Our interpretation of the data is based on pub-
ished information and one logical but hypothetical model
f a possible sequence of events involving impaired endo-
helial apoptosis, intimal proliferation, and PHT (5,18).
urther studies would be required to better understand the
ctual pathophysiological sequence of events. In summary,
ur current findings highlight the roles of impaired endo-
helial cell apoptosis and inflammatory cell apoptosis in the
athogenesis of irreversible PHT complicating CHD.
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